Hideo Nakamura

Department of Neurosurgery, Kurume University School of Medicine

Disclosure: Nothing to disclose

Presentation(s):

• ACTR-04 - BIOMARK: A phase II study of bevacizumab beyond progression for newly diagnosed glioblastoma: Safety, efficacy and prospective biomarker analysis

  Friday, November 22
  2:00 PM – 2:10 PM

• TMOD-33 - An integrated approach combining mathematical and genomic methods to reveal the optimal timing of therapeutic intervention in WHO grade II diffuse glioma

  Saturday, November 23
  5:00 PM – 7:00 PM